Recent Publications

Cohen A, Spektor TM, Stampleman, Bessudo A, Rosen PJ, Klein LM, Woliver T, Flam M, Eshaghian S, Nassir Y, Swift RA, Vescio R, and Berenson JR, “Safety and Efficacy of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed and Refractory Multiple Myeloma,” Brit J Haematol. 180:60-70 (2018).
View Article

Vidisheva AP, Wang J, Spektor TM, Bitran JD, Lutzky J, Tabbara IA, Ye JZ, Ailawadhi S, Stampleman LV, Steis RG, Moezi MM, Swift RA, Maluso TM, Udd KA, Eshaghian S, Nassir Y, and Berenson JR, “Manifestation of Peripheral Neuropathy in Multiple Myeloma Patients with Bortezomib Retreatment,” J Supportive Care Cancer. e-published on April 28, 2017.
View Article

Boccia RV, Bessudo A, Agajanian A, Conkling P, Harb W, Yang H, Pinchasik D, Kimball AS, and Berenson JR, “A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2),” Clinical Lymphoma, Myeloma and Leukemia 17:433-437 (2017).
View Article

Berenson J, Cartmell A, Bessudo A, Lyons R, Harb W, Tzachanis D, Agajanian R, Boccia R, Coleman M, Moss RA, Rifkin RM, Patel P, Dixon S, Ou Y, Anderl J, Aggarwal S, and Berdeja JG, “Results of CHAMPION-1: A Phase 1/2 Study of Weekly Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma,” Blood, 127(26):3360-68 July (2016).
View Article

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy
Leukemia, January 2014
View Article

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.
Annals of Hematology, January 2014
View Abstract

Phase I/II Trial Assessing Bendamustine plus Bortezomib Combination Therapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
British Journal of Haematology, February 2013
View Abstract

A Phase 2 Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Patients with Relapsed/Refractory Multiple Myeloma
Leukemia, July 2012.
View Abstract

A Modified Regimen of Pegylated Liposomal Doxorubicin, Bortezomib, and Dexamethasone is Effective and Well Tolerated in Frontline Treatment of Multiple Myeloma
British Journal of Haematology, December 2011
View Article

A Retrospective Study to Evaluate the Work up and Follow up of Patients with Monoclonal Gammopathy of Undetermined Significance
Clinical Lymphoma, Myeloma and Leukemia, August 2011
View Abstract

Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid
American Journal of Hematology, January 2011
View Article